Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
The prognosis of cancer patients is poor. To improve the prognosis of cancer patients, variable approaches are necessary. Imaging mass-spectrometry (IMS) is a novel technology, which enables one to viisualize the distribution of hundreds of metabloite in tissues. Using this novel technology, we treid to clarify the mechansims of efficacy of some anti-cancer agents. We focused on anti-angiogenic agents such as nintedanib or bevacizumab. We partly clarified the mechanisms of efficacy of these agents by in vivo experiments with IMS. The findings will help developing an effective and appropriate treatement using anti-angiogenic agents.
|